Antiviral drug development--success and failure: a personal perspective with a Japanese connection.
De Clercq E.
Antivir Chem Chemother · review; journal article · DOI 10.3851/imp2396 PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för elvitegravir. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
22 hitsA randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results.
Rockstroh JK, DeJesus E, Henry K, Molina JM, Gathe J, Ramanathan S, Wei X, Plummer A, Abram M, Cheng AK, Fordyce MW, Szwarcberg J, GS-236-0103 Study Team.
J Acquir Immune Defic Syndr · clinical trial, phase iii; comparative study; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1097/qai.0b013e318286415cClinical use of HIV integrase inhibitors: a systematic review and meta-analysis.
Messiaen P, Wensing AM, Fun A, Nijhuis M, Brusselaers N, Vandekerckhove L.
PLoS One · meta-analysis; research-article; systematic review; journal article · DOI 10.1371/journal.pone.0052562Prevalence of primary resistance mutations to integrase inhibitors in treatment-naïve and -experienced patients infected with B and non-B HIV-1 variants.
Gutiérrez C, Hernández-Novoa B, Pérez-Elías MJ, Moreno AM, Holguín A, Dronda F, Casado JL, Moreno S.
HIV Clin Trials · research support, non-u.s. gov't; multicenter study; journal article · DOI 10.1310/hct1401-10Exploring the molecular mechanism of cross-resistance to HIV-1 integrase strand transfer inhibitors by molecular dynamics simulation and residue interaction network analysis.
Xue W, Jin X, Ning L, Wang M, Liu H, Yao X.
J Chem Inf Model · research support, non-u.s. gov't; journal article · DOI 10.1021/ci300541cMultiple choices for HIV therapy with integrase strand transfer inhibitors.
Raffi F, Wainberg MA.
Retrovirology · research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/1742-4690-9-110Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single tablet for HIV-1 infection treatment.
Olin JL, Spooner LM, Klibanov OM.
Ann Pharmacother · comparative study; review; journal article · DOI 10.1345/aph.1r468Effects of etravirine on the pharmacokinetics of the integrase inhibitor S/GSK1265744.
Ford SL, Gould E, Chen S, Lou Y, Dumont E, Spreen W, Piscitelli S.
Antimicrob Agents Chemother · clinical trial; research support, non-u.s. gov't; research-article; journal article · DOI 10.1128/aac.01685-12Ruthenium arene complexes as HIV-1 integrase strand transfer inhibitors.
Carcelli M, Bacchi A, Pelagatti P, Rispoli G, Rogolino D, Sanchez TW, Sechi M, Neamati N.
J Inorg Biochem · research support, non-u.s. gov't; journal article · DOI 10.1016/j.jinorgbio.2012.09.021Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens.
Smith RA, Raugi DN, Pan C, Coyne M, Hernandez A, Church B, Parker K, Mullins JI, Sow PS, Gottlieb GS, University of Washington-Dakar HIV-2 Study Group.
PLoS One · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1371/journal.pone.0045372Pharmacology of HIV integrase inhibitors.
Adams JL, Greener BN, Kashuba AD.
Curr Opin HIV AIDS · research support, non-u.s. gov't; research-article; review; journal article; research support, n.i.h., extramural · DOI 10.1097/coh.0b013e328356e91cTolerability of HIV integrase inhibitors.
Lee FJ, Carr A.
Curr Opin HIV AIDS · review; journal article · DOI 10.1097/coh.0b013e328356682aUpdate on raltegravir and the development of new integrase strand transfer inhibitors.
Shamroe CL, Bookstaver PB, Rokas KE, Weissman SB.
South Med J · research support, non-u.s. gov't; review; journal article · DOI 10.1097/smj.0b013e318258c847The elvitegravir Quad pill: the first once-daily dual-target anti-HIV tablet.
Marchand C.
Expert Opin Investig Drugs · research support, n.i.h., intramural; editorial · DOI 10.1517/13543784.2012.685653Elvitegravir: a once-daily inhibitor of HIV-1 integrase.
Wills T, Vega V.
Expert Opin Investig Drugs · comparative study; review; journal article · DOI 10.1517/13543784.2012.658914Homology model-guided 3D-QSAR studies of HIV-1 integrase inhibitors.
Sharma H, Cheng X, Buolamwini JK.
J Chem Inf Model · research support, non-u.s. gov't; journal article; research support, n.i.h., extramural · DOI 10.1021/ci200485aReview of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settings.
Lee JS, Calmy A, Andrieux-Meyer I, Ford N.
HIV AIDS (Auckl) · review-article; journal article · DOI 10.2147/hiv.s20993In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4.
Margot NA, Hluhanich RM, Jones GS, Andreatta KN, Tsiang M, McColl DJ, White KL, Miller MD.
Antiviral Res · journal article · DOI 10.1016/j.antiviral.2011.12.008Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study.
Molina JM, Lamarca A, Andrade-Villanueva J, Clotet B, Clumeck N, Liu YP, Zhong L, Margot N, Cheng AK, Chuck SL, Study 145 Team.
Lancet Infect Dis · clinical trial, phase iii; comparative study; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/s1473-3099(11)70249-3Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143.
Métifiot M, Vandegraaff N, Maddali K, Naumova A, Zhang X, Rhodes D, Marchand C, Pommier Y.
AIDS · research support, n.i.h., intramural; research-article; journal article · DOI 10.1097/qad.0b013e3283473599Development of integrase inhibitors of quinolone acid derivatives for treatment of AIDS: an overview.
Luo ZG, Tan JJ, Zeng Y, Wang CX, Hu LM.
Mini Rev Med Chem · review; journal article · DOI 10.2174/1389557511009011046Integrase inhibitors: a novel class of antiretroviral agents.
Schafer JJ, Squires KE.
Ann Pharmacother · review; journal article · DOI 10.1345/aph.1m309